<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kiniksa Pharmaceuticals Ltd — News on 6ix</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd</link>
<description>Latest news and press releases for Kiniksa Pharmaceuticals Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kiniksa-pharmaceuticals-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358e8b78dffbe2df10142b.webp</url>
<title>Kiniksa Pharmaceuticals Ltd</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd</link>
</image>
<item>
<title>Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-april-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-april-28-2026</guid>
<pubDate>Thu, 23 Apr 2026 20:01:00 GMT</pubDate>
<description>LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may registe</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-launches-targeted-direct-to-consumer-tv-campaign-for-arcalystr-rilonacept-in-recurrent-pericarditis</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-launches-targeted-direct-to-consumer-tv-campaign-for-arcalystr-rilonacept-in-recurrent-pericarditis</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-to-present-at-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-to-present-at-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 21:01:00 GMT</pubDate>
<description>LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hour</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-portfolio-execution</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-portfolio-execution</guid>
<pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
<description>– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-24-2026</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-24-2026</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via tele</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Provides Corporate Update</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-provides-corporate-123000630</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-provides-corporate-123000630</guid>
<pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
<description>– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by year end –– Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) – LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-present-44th-annual-210100416</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-present-44th-annual-210100416</guid>
<pubDate>Wed, 07 Jan 2026 21:01:00 GMT</pubDate>
<description>LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-present-jefferies-global-healthcare-conference-london-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-present-jefferies-global-healthcare-conference-london-2025-11</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-third-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-third-quarter-2025-financial-results-and-recent</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-report-third-quarter-2025-financial-results-october-28-2025</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-report-third-quarter-2025-financial-results-october-28-2025</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-announces-us-orphan-drug-designation-kpl-387-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-announces-us-orphan-drug-designation-kpl-387-treatment</guid>
<pubDate>Fri, 17 Oct 2025 04:00:00 GMT</pubDate>
<description>LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-present-upcoming-investor-conferences-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-present-upcoming-investor-conferences-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-second-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-second-quarter-2025-financial-results-and-recent</guid>
<pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
<description>– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-report-second-quarter-2025-financial-results-july-29-2025</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-report-second-quarter-2025-financial-results-july-29-2025</guid>
<pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
<description>LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-announces-trial-design-planned-phase-2-3-clinical-trial-kpl</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-announces-trial-design-planned-phase-2-3-clinical-trial-kpl</guid>
<pubDate>Thu, 05 Jun 2025 04:00:00 GMT</pubDate>
<description>– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-announces-grammyr-award-winning-country-star-carly-pearce</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-announces-grammyr-award-winning-country-star-carly-pearce</guid>
<pubDate>Wed, 30 Apr 2025 04:00:00 GMT</pubDate>
<description>– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-first-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-first-quarter-2025-financial-results-and-recent</guid>
<pubDate>Tue, 29 Apr 2025 04:00:00 GMT</pubDate>
<description>– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-report-first-quarter-2025-financial-results-april-29-2025</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-report-first-quarter-2025-financial-results-april-29-2025</guid>
<pubDate>Thu, 24 Apr 2025 04:00:00 GMT</pubDate>
<description>LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results</guid>
<pubDate>Tue, 25 Feb 2025 05:00:00 GMT</pubDate>
<description>– ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product</description>
</item>
<item>
<title>Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy</title>
<link>https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-announces-development-kpl-387-recurrent-pericarditis-and</link>
<guid isPermaLink="true">https://6ix.com/company/kiniksa-pharmaceuticals-ltd/news/kiniksa-pharmaceuticals-announces-development-kpl-387-recurrent-pericarditis-and</guid>
<pubDate>Tue, 25 Feb 2025 05:00:00 GMT</pubDate>
<description>– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascending dose data support</description>
</item>
</channel>
</rss>